Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CD34 CAR T Cells in B Cell Malignancies
NCT04214886Phase 1Active, not recruiting
- Sponsor
- Loyola University Chicago
- Start
- Dec 2019
- Primary completion
- Aug 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD19-CD34 CAR transduced T cells in acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (B-NHL) (4 arms), sponsored by Loyola University Chicago. Primary endpoints: Successful production of CD19-CD34 CAR product at 18 months and Adverse events at 15 years. Started Dec 2019; status: active, not recruiting.
02
Drugs
CD19-CD34 CAR transduced T cells
03
Conditions
acute lymphoblastic leukemia (ALL)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT04214886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04214886.